GlobeNewsWire
13 Aug 2026, 11:36 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Clearmind Medicine's CMND-100 achieved its primary safety endpoint in Part A of its Phase I/II clinical trial, showing a favorable safety and tolerability profile. — Meeting primary safety endpoints is a critical de-risking event for clinical-stage biotech companies and is typically viewed as a prerequisite for any future valuation increase.
+0.60The Independent Data and Safety Monitoring Board (DSMB) has unanimously approved advancing the trial to Parts B and C, which include testing in patients with Alcohol Use Disorder (AUD). — Moving from healthy volunteers to the actual target patient population is a major clinical milestone that brings the company closer to demonstrating efficacy.
+0.40CMND-100 is designed as a non-hallucinogenic neuroplastogen, intending to avoid the perceptual effects and intensive clinical supervision required by classical psychedelics. — A non-hallucinogenic profile suggests a more scalable commercial model and lower regulatory hurdles compared to traditional psychedelic therapies.
+0.20Continue reading
6 related stories
Search tags
Which stocks this story touches
The company achieved its primary safety endpoint and received DSMB approval to advance its clinical trial of CMND-100 to patients with Alcohol Use Disorder.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
